Recent Updates — CRVO

CervoMed Inc. announced initial data from the first 12 weeks of its open-label Phase 2a clinical trial for neflamapimod in nonfluent variant primary progressive aphasia (nfvPPA). The company reported a mean reduction in plasma neurofilament light chain (NfL) levels of approximately 3.1 pg/mL across all participants, with a more pronounced decline of ~5.7 pg/mL observed in the subgroup with baseline NfL levels at or above the median. Glial fibrillary acidic protein (GFAP) levels remained stable during this period. The findings were presented as a late-breaking oral session at the 15th International Society of Frontotemporal Dementias Annual Meeting. CervoMed expects to present 24-week biomarker data in November 2026 and topline clinical data in early 2027. CervoMed is a clinical-stage company developing treatments for age-related brain disorders, with its lead candidate neflamapimod targeting neuroinflammation.